10/586899 AP20 Rec'd PCT/PTO 21 JUL 2006

Attorney Docket No.: 10534.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bjornvad

Confirmation No: To be assigned

Serial No.: TBA

Group Art Unit: To be assigned

Filed: July 21, 2006

Examiner: To be assigned

For: Method for Testing or Screening for an Enzyme of Interest

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 21, 2006

Jason/I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212)840-0097

AP20 Rec'd PCT/PTO 21 JUL 2006

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Pape	ELMOIK LEGUCTION	<u>ACLOI 1995, NO PEISC</u>	ons are required to r	espond to a collection of information unless	
Substitute for form 1449A/PTO				Comple	ete if Known
1				Application Number	TBA O O O O O O O
INFORMATION DISCLOSURE				Filing Date	July 21, 2006
STATEMENT BY APPLICANT (use as many sheets as necessary)			ANT	First Named Inventor	Bjornvad
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	10534.204-US

		U.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 5,208,148	05-04-1993	Haugland et al	<u> </u>
		US 5,605,809	02-25-1997	Komoriya et al	
		US 5,830,912	11-03-1998	Gee et al	
		US 2003/0207345	11-06-2003	Arnold et al	
		US 4,492,754	01-08-1985	Trager et al	
					·
	-				
		<u> </u>			
	1				
	\neg				
	1	· -			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code 3 – Number 4 – Kind Code 5 (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 93/11249	06-10-1993	Novo Nordisk		
		WO 01/57237	08-09-2001	Amersham		
	 					
	 					
	 					
	 					
						
			ļ			
	ļ					
		<u> </u>				

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

AP20 Rec'd PCT/PTO 21 JUL 2006

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute 1	for form 1449A/PTO			Сотрі	ete if Known / COAQOI
				Application Number	TEAU / DOOD Y
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			JRE	Filing Date	July 21, 2006
			ANT	First Named Inventor	Bjornvad
				Art Unit	To be assigned
	,			Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	10534.204-US

Examiner's	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Initials	No. 1	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T ²
		Risna et al, Fungal Diversity, Vol. 9, pages 123-134 (2002)	
			_
	1		
	1		
	1		
	 		
	<u> </u>		
	 		-
	1		

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.